益生菌 (Probiotics) 和 益菌生 (Prebiotics)共同打擊幼兒異位性皮膚炎

Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol. 2012 Jan;166(1):129-36. Wu KG, Li TH, Peng HJ. Source: Departments of Pediatrics Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan Department of Pediatrics, Hualien Armed Forces General Hospital, Hualien, Taiwan.

Background: Some probiotics can ameliorate childhood atopic dermatitis (AD). Prebiotics have also shown some efficacy, although when combined with probiotics as synbiotics, their efficacy may improve. Objective: We compared the effects of Lactobacillus salivarius and fructo-oligosaccharide (synbiotic) with fructo-oligosaccharide alone (prebiotic) on children with moderate to severe AD. Methods? We randomly assigned 60 children aged 2-14?years with moderate to severe AD [SCORing AD (SCORAD) >?25] to a treatment (synbiotic) or a control (prebiotic) group (30 per group). They received one capsule twice daily for 8?weeks containing either L. salivarius plus fructo-oligosaccharide (treatment) or fructo-oligosaccharide only (control). SCORAD indices were monitored at weeks 0, 4, 8 and 10 (post-treatment). Laboratory results and AD medication use were also monitored. Results? Baseline demographic and clinical characteristics and SCORAD scores were similar between the two groups. At 8?weeks, the treatment group SCORAD scores (27·4?±?12·7) were significantly lower than for the controls (36·3?±?14·9) (P?=?0·022); this difference remained at 10?weeks. At 8?weeks, treatment group AD intensity was significantly lower (P?=?0·013); more children had mild AD in the treatment group (52%; 14/27) than the control group (30%; 8/27) (P?=?0·024). Medication use frequency and eosinophil cationic protein levels were significantly reduced in the treatment group at 8?weeks compared with 4?weeks. Conclusion? A synbiotic combination of L. salivarius plus fructo-oligosaccharide is superior to the prebiotic alone for treating moderate to severe childhood AD. However, continued follow-up will be necessary to ascertain long-term benefits.

TFDA盯上牛樟芝產品 難有模糊空間!

預告訂定「食品中真菌成分檢驗方法—牛樟芝成分之檢驗」，為食品衛生管理法所定之食品衛生檢驗方法。 (TFDA發布日期2012-01-16) 主旨：預告訂定「食品中真菌成分檢驗方法—牛樟芝成分之檢驗」，為食品衛生管理法所定之食品衛生檢驗方法。依據：行政程序法第一百五十四條第一項。公告事項：一、訂定機關：行政院衛生署。二、訂定依據：食品衛生管理法第二十五條。三、草案內容如附件。本案另載於本署網站（網址：http://www.doh.gov.tw）之網頁及行政院衛生署食品藥物管理局網站 （網址：http://www.fda.gov.tw）之「本局公告」網頁。四、對於本公告內容有任何意見或修正建議，請於本公告刊登公報之次日起20日內陳述意見或洽詢：

優你康 將走出夾殺空間!!

 

優你康大擴產 八條線路今年到位【2012/01/17 經濟日報】隱形眼鏡廠優你康（4150）董事長劉永泉昨16日宣布，自有品牌「高視能」（iVisi n）元年啟動，並正式發表彩色片新產品。劉永泉說，今年要擴八條新產線，產能超過1. 2億片。法人估，該公司今年每股稅後純益將創歷史新高。 優你康成立於1992年，旗下有隱形眼鏡自有品牌「高視能」，目前為東南亞前三大拋棄式隱形眼鏡製造商。該公司去年營收約4.3億元，在隱形眼鏡的製造毛利率約40%。優你康昨日興櫃參考價為60元。 優你康昨日旗下自有品牌「高視能」舉行新品發表會；公司表示，去年內部進行製程改善，讓第四季獲利開始回溫，營運轉正，預估毛利率將提升到50%以上。法人預估，今年優你康獲利將在第三季爆發，若以產能倍數換算，今年營收可望超過10億元，而稅後純益也可望上看3億元。

Cabinet to Push Chinese “Medical Cloud”

 2012/01/17 Taipei, Jan. 17, 2012 (CENS)--The scientific and technological coordination panel under the Executive Yuan (the Cabinet) will enter a strategic alliance with IBM, NEC, Acer, and other major domestic ICT (information and communications technology) in June this year for developing the world's largest Chinese "medical cloud." The medical cloud will build up abundant medical information and develop 30 different kinds of business models, creating NT$10 billion of business opportunity. In addition to Acer, the project will benefit many domestic ICT firms, including Quanta, Inventec, and Hon Hai, as well as Chunghwa Telecom, Far Eastone, and Taiwan Mobile. The project will be publicized during an "open data" strategic meeting to be convened by the scientific and technological coordination panel tomorrow (Jan. 18), which will be attended by more than 200 persons. The project is a result of the visit by Cyrus Chu, deputy convener of the scientific and technological coordination panel, to NEC and Fujitsu last December. Taiwan and Japan will sign a memorandum of understanding for medical cloud project in the first half this year, and ACER and IBM will also take part in the project. IBM will provide the core technology for the project. Taiwan's health insurance program possesses the world's largest Chinese medical treatment database. Under the project, the Bureau of National Health Insurance will provide health insurance data, while National Taiwan University Hospital and National Cheng Kung University Hospital will provide medical treatment data. The Bureau of National Health Insurance will combine the two data and delete information on local people's identity before providing them to sci-tech firms for the establishment of cloud-end computing center and production of valuable information, for license to international pharmaceutical firms. In addition to the establishment of computing center, major sci-tech firms will also take charge of international marketing.

泉盛與龍瑞藥業 開發Xolair相似藥物!!

中天結盟港商 衝業績【2012/01/18 經濟日報】中天生技（4128）昨（17）日宣布，旗下轉投資生技新藥公司泉盛將與香港晨興集團合作，與晨興旗下龍瑞藥業合作開發Xolair生物相似藥物；未來雙方可望共同搶攻全球10億美元（約新台幣300億元）市場。中天生技昨日股價以38.3元作收，上漲1.3元；該公司去年前三季稅後純益約3.38億元，每股稅後純益1.24元。 泉盛董事長林衛理說，公司將在今年2月15日前，和香港晨興集團屬下的深圳龍瑞藥業簽訂合作意向書，共同在大陸開發「治療過敏抗體新藥」Xolair的生物相似藥。 未來，將由龍瑞藥業負責「臨床前試驗」（IND）階段，並由龍瑞向大陸藥品監管局（SFDA）申請臨床階段，隨後就由泉盛接手負責完成，一直到新藥藥證登錄（NDA）。 泉盛說，龍瑞所屬的香港晨星集團，不僅是亞洲最大的生技創投公司之一，也稱得上市全球生技創投數一數二的大集團；此外，該集團在大陸擁有最完整的抗體藥物開發、生產基地，若要進軍大陸抗體市場，將是不二人選。泉盛說，目前雙方正在就未來銷售獲利的權利金分拆方式進行細節協商，近期可望獲得共識並簽署合作契約。未來，雙方合作將可加速Xolair生物相似藥在大陸開發時程，大幅減少初期研發費用與降低研發風險。泉盛表示，未來該藥品的開發階段，將以國際級的標準進行。